Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
NCT Number: NCT04495218
Implementation of a next-generation sequencing panel of genes to identify deleterious variants in patients with incomplete forms of albinism.
Looking for future studies?
Notify Me0 year and older
All sexes
Observational
Bordeaux, France
Scientific context : Albinism is clinically characterised by cutaneous hypopigmentation and ophthalmologic features. These features common to all forms of albinism are foveal hypoplasia, misrouting of the optic nerves at the chiasm, retinal hypopigmentation, translucent irides and nystagmus. The molecular genetic lab at Bordeaux University Hospital is the national reference for the study of this disease. More than 1400 patients have been analyzed with a strategy including next-generation sequencing of the 19 known genes of albinism and array-CGH. Despite this thorough analysis, 25% of patients remain without molecular diagnosis. Our experience tells us that these patients often show an incomplete form of albinism with the presence of only few ophthalmologic signs. The molecular diagnosis is very challenging as the phenotype often overlaps with other ophthalmologic disorders.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
Time frame: Enrollment
the prevalence of finding at least two pathogenic variants is 10%.
University Hospital, Bordeaux
Other
Implementation of a Next-generation Sequencing Analysis of a Panel of Genes Implicated in Incomplete Forms of Albinism
Acronym: DIA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001153
Albinism, Albinism, Ocular
Bethesda, Maryland, United States
View Trial DetailsNCT03959605
Albinism, Albinism, Ocular
Paris, France
View Trial DetailsNCT06345976
Albinism, Albinism, Ocular
Paris, France
View Trial DetailsNCT04658381
Albinism, Amino Acid Metabolism, Inborn Errors
Paris, France
View Trial Details